Navigation Links
Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference

MINNEAPOLIS, Feb. 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that it will be presenting at the ROTH Capital Partners OC Growth Conference on Wednesday, February 20, 2008 at the Ritz Carlton Laguna Nigel. David Kaysen, Uroplasty's President and CEO and Medi Jiwani, Uroplasty's Vice President and CFO, will present the Company's business strategy and financial results at 4:00 p.m. Pacific Time.

Attendance at the conference is by invitation only. A live audio-only webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at Uroplasty's website at An archived replay of the presentation will also be available shortly after the live presentation at Uroplasty's website.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Uroplasty Expands Marketing Program for Urology Practices
2. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
3. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
4. Uroplasty to Host Second Quarter Conference Call on November 1
5. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
6. HMS Holdings Corp. to Present at 2008 UBS Global Healthcare Services Conference
7. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
8. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
9. Vical to Present at BIO CEO and Investor Conference
10. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
11. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology: